Cambridge Investment Research Advisors
CBRS

Cambridge Investment Research Advisors’s Cerebras Systems CBRS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CBRS Stock Details CBRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Buy
+9,683
New +$2.28M ﹤0.01% 1639

Other funds holding CBRS

WU
Washington University St Louis, Missouri $265M AUM 9.03% 1-Year Est. Return
LAI
Legal Advantage Investments Los Altos Hills, California $285M AUM 18.63% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
RS
Robeco Schweiz Zurich, Switzerland $6.23B AUM 86.54% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
TEC
Tensor Edge Capital Weston, Massachusetts $1.51B AUM

Cambridge Investment Research Advisors's CBRS Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in Cerebras Systems (CBRS) in Q2 2026: 9,683 shares worth $2.14M. The stake represents ﹤0.01% of the portfolio and ranks #1639 among its holdings.

120 funds tracked by Wall St. Rank hold CBRS as of Q2 2026.

  • Cambridge Investment Research Advisors held 9,683 shares of Cerebras Systems worth $2.14M as of Q2 2026.
  • Cerebras Systems was a new Cambridge Investment Research Advisors position in Q2 2026.
  • Cerebras Systems made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1639 holding.
  • 120 funds tracked by Wall St. Rank held Cerebras Systems as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.